FDA

The FDA granted accelerated approval to Inovio’s Voceryq, the first plasmid DNA-based immunotherapy in the U.S., for adults with recurrent respiratory papillomatosis. Here’s what the data show and why the approval matters for biotech and healthcare businesses.